NOVADIP Appoints Eric Paul P‚ques as Chairman of the Board

Tuesday, May 30, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

MONT-SAINT-GUIBERT, Belgium, May 30, 2017 /PRNewswire/ --

Advanced biopharmaceutical company NOVADIP BIOSCIENCES, which pioneers the growth of 3-dimensional tissues derived from adipose stem cells to regenerate bone and soft tissues, announces that

Mr. Eric Paul P‚ques has been appointed as Chairman of the Board of Directors. With his strong experience leading the GrŁnenthal Group to impressive growth, combined with his proficiency in pharmaceutical R&D, Mr. P‚ques is well-positioned to support Novadip Biosciences in the next phases of
its international development.

†For over 20 years, Mr. P‚ques played a key role in the success of the research-based, family-owned pharmaceutical company GrŁnenthal Group (Aachen, Germany), including as CEO and Chairman of the Executive Board from 2013 through 2016. Mr. P‚ques holds a Ph.D. of Biochemistry from Max-Planck Institute (Germany) and Universitť catholique de Louvain (Belgium), and completed the Advanced Management Programme of INSEAD (France). He has published more than 70 articles and secured more than 30 patents. He sits on the Boards of a number of companies as well as foundations and academies and teaches at the RWTH-University (Germany).

"Appointing Eric Paul as Chairman of the Board marks an important step in Novadip's development," comments Jean-Francois Pollet, CEO of Novadip Biosciences. "He brings a remarkable expertise not only in driving organisational growth, but also in strengthening R&D activities and portfolios to meet today's regulatory, operational and commercial demands. With his track record of successful approvals for pharmaceutical products arising from R&D, he has in-depth understanding of what is needed in order to maximize the performance of our new products."

"Eric Paul has a strong international outlook combined with proven skills in developing partnerships with major players in the advanced pharmaceutical industry," adds Denis Dufrane, CSO of Novadip Biosciences "We are delighted that he will bring his dedication to the role of Chairman of the Board, and are confident that his support will be decisive as our fast-growing company extends the potential of its innovative therapies."

"Eric Paul is a highly respected industry executive with a compelling expertise in the pharmaceutical industry " highlights Philippe Durieux, former Chairman of the Board and CEO of Sopartec and VIVES Fund. "We are honoured that a top executive of his calibre has accepted to join a UCL spin-off company. This decision also validates our attractiveness in pioneering and sustainable technologies."

Mr. P‚ques expressed his pleasure at being appointed Chairman of the Board of Novadip Biosciences: "I am excited to join Novadip's board of directors and to support the talented team of innovators working together with Jean-Francois and Denis. Regenerative medicine is rapidly evolving and the proprietary technology developed at Novadip has the potential to provide a breakthrough therapy in multiple indications with very high medical needs".


Founded in 2013 by Dr. Denis Dufrane and Dr. Jean-FranÁois Pollet, Novadip Biosciences is a regenerative medicine spin-off company from Universitť catholique de Louvain (UCL) and St. Luc University Hospital. The creation of Novadip Biosciences was supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II. Novadip Biosciences pioneers the growth of 3-dimensional biologics based on adipose-derived stem cells, to regenerate hard and soft tissues. The flagship of the company's product family is NVD-001, a revolutionary, ready-to-use and biological 3D osteogenic structure that can be modelled to fill any bone defects. The technology has also been used to develop the second family product in the portfolio, NVD-002, a biological bandage for skin tissue applications, designed to avoid formation of painful scars.

Web : †


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store